Buzzetti, M, Morlando, S, Solomos, D, Mehmood, D, Cox, AWI, Chiesa, M, D’Alessandra, Y, Garofalo, M, Topham, CH and Di Leva, G (2021) Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells. Scientific Reports, 11 (1). ISSN 2045-2322

[thumbnail of Buzzetti et al. 2019 - Text 1st revision- Scientific reports.docx] Text
Buzzetti et al. 2019 - Text 1st revision- Scientific reports.docx - Accepted Version
Restricted to Repository staff only
Available under License Creative Commons Attribution Non-commercial.

Download (142kB)
[thumbnail of Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.pdf]
Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.pdf - Published Version
Available under License Creative Commons Attribution.

Download (3MB) | Preview


Medulloblastoma (MB) is the most common aggressive paediatric brain tumour and, despite the recent progress in the treatments of MB patients, there is still an urgent need of complementary or alternative therapeutic options for MB infants. Cyclin Dependent Kinase inhibitors (CDKi) are at the front-line of novel targeted treatments for multiple cancers and the CDK4/6 specific inhibitor palbociclib has been pre-clinically identified as an effective option for MB cells. Herein, we identified the pan-CDKi dinaciclib as a promising alternative to palbociclib for the suppression of MB cells proliferation. We present evidence supporting dinaciclib’s ability to inhibit MB cells in vitro proliferation at considerably lower doses than palbociclib. Sequencing data and pathway analysis suggested that dinaciclib is a potent cell death inducer in MB cells. We found that dinaciclib-induced apoptosis is triggered by CDK9 inhibition and the resultant reduction in RNA pol II phosphorylation, which leads to the downregulation of the oncogenic marker MYC, and the anti-apoptotic protein MCL-1. Specifically, we demonstrated that MCL-1 is a key apoptotic mediator for MB cells and co-treatment of dinaciclib with BH3 mimetics boosts the therapeutic efficacy of dinaciclib. Together, these findings highlight the potential of multi-CDK inhibition by dinaciclib as an alternative option to CDK4/6 specific inhibition, frequently associated with drug resistance in patients.

Item Type: Article
Additional Information: This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Nature Publishing Group at - please refer to any applicable terms of use of the publisher.
Uncontrolled Keywords: cancer; molecular medicine
Subjects: R Medicine > R Medicine (General) > R735 Medical education. Medical schools. Research
R Medicine > RZ Other systems of medicine
Divisions: Faculty of Medicine and Health Sciences > School of Pharmacy and Bioengineering
Depositing User: Symplectic
Date Deposited: 02 Mar 2021 16:21
Last Modified: 11 Jun 2021 13:36

Actions (login required)

View Item
View Item